GENERAL COMMENTS
This research theme is interesting and new as we don't have conclusive results on jaw ON and S's S. In abstract, for design, I think the type of study could be noted also just like in the tile, cohort study. The second point for study strengths and limitations it's a conclusion. For example, the fact that in the data set are present only 5 diagnosis could be a limitation. The tobacco use is noted as risk factor for ON and could be also an important confounder (as noted in the last part). Maybe it's possible to identify using the ICD-9 codes disease related to tobacco use (eg COPD). The same for alcohol-related disorders.
REVIEWER

Farya Domah
University of Central Lancashire, Oral Surgery REVIEW RETURNED 02-Aug-2018
GENERAL COMMENTS
It is obvious that here is a lot of work that has been invested in the study. Very large number of patients looked at to allow for statistical analysis.
The study is informative and readers are highly likely to learn something new.
Is there a reason for looking at bisphosphonates only and not at all anti-resorptive medication?
I found the methodology difficult to follow and lacks clarity. It may have been in an attempt to reduce the word count and unfortunately some important information was omitted. It is not in the text whether all the ONJ patients had surgical extractions. It was apparent from Figure 1 .
--------------------------------------------------------------------------------------------Abstract Objectives
Osteonecrosis of the jaw (ONJ) could have detrimental effects on patients. I would use instead: Osteonecrosis of the jaw (ONJ) has detrimental effects on patients.
A long duration of the use of Bisphosphonates (BPs) I would use instead: Long term use of bisphosphonates (BPs).
Patients with Sjögren's syndrome (SS) could have impaired oral hygiene due to xerostomia I would use a different statement to introduce Sjogren syndrome. Something to link the statements. Possibly: Similarly, Sjogren syndrome affects patients' quality of life. Or a statement along these lines.
Aim
Here, the aim is to determine whether patients with SS were susceptible to BRONJ. Later on in the text it says 'the primary endpoint of the study was to determine whether SS patients exhibit an increased risk of developing ONJ' Are you looking exclusively at patients with SS on bisphosphonates who subsequently develop BRONJ or patients with SS who develop ONJ without antiresorptive medication? or both?
We aim to test whether patients I would use instead: We aim to determine Design What was the design of the study? retrospective? cross sectional? from 2000 to 2013. A database extracted from Taiwan's National Health Insurance Research Database (NHIRD) were used. I would use instead: Data was extracted from Taiwan's National Health Insurance Reasearch Database (NHIRD). This is part of the methods.
Methods
All medical conditions for each case and control were categorized using the International Classification of Diseases I would use instead: Medical conditions for both the study and control group were categorised..
Results
In total, 13,398 patients diagnosed with SS were identified in the NHIRD. An additional 53,592 matched patients were designated the controls. I would use instead: 13,398 patients diagnosed with SS were identified from the NHIRD. An additional 53,592 matched patients formed the control group. If the date of SS diagnosis is the index date, it seems to me that it does not make sense adding that "those diagnosed with SS […] prior to the index date" were excluded" (page 8 line 46). Radiotherapy is an exclusion criterion for BRONJ, rather than a "relevant comorbidity" (page 9 line 12). Why was osteoporosis not among the conditions identified? Was it possible to distinguish between bisphosphonates with oncological indications from those prescribed for osteoporosis?
According to Figure 1 the number of BISPHOSPHONATE-RELATED osteonecrosis of the jaw is 4. While it is unclear the number of BISPHOSPHONATE-RELATED cases in the group without SS. How Authors explain the high difference in the prevalence of diabetes (2 times) and malignancies (1.5 times)? Not surprisingly, the use of steroids is 75 times more common among SS patients. I wonder if this can be the only possible explanation of the difference in BRONJ incidence. Please check this hypothesis. The use of bisphosphonates as reported in the table it is not particularly useful unless it can be stratified according to the indication (metastasis vs osteoporosis). The risk is of the two types of drugs is too much different to be analysed together.
REVIEWER
Bethan Copsey
University of Oxford, United Kingdom REVIEW RETURNED 28-Sep-2018
GENERAL COMMENTS
Bethan Copsey University of Oxford, United Kingdom 28-Sep-20The authors should be commended for a manuscript that is clear and well-written.
The analyses are appropriate for the study design and the study limitations regarding confounded are clearly stated. However, I would like clarification in the text on the analyses that were performed.
1a. Please could you provide additional details on the matching process in the methods section. The methods section suggests that participants were matched on identical covariate values (age and gender). However, figure 1 contradicts this by saying propensity score matching was used.
1b. In addition, presumably the index date for the patient cohort was then assigned to the corresponding control patients, rather than this being a matching criteria since the control patients won't have a diagnosis date?
2. The insignificant results for steroids, chemotherapy and radiotherapy could be due to the low number of events. Please mention this in the limitations and be more cautious in your conclusions regarding these results.
3. Please provide additional results on the interaction model. Was this adjusted for the other covariates as well as those in the interaction term? Please report the raw numbers and percentages for those in the corresponding biphosphonate x ONJ groups.
4. Please amend the incorrect percentage for Steroids in Table 1 (4.14.71%).
5. This study focuses on ONJ after tooth extraction. Could it be that SS patients have higher risk of needing tooth extraction which causes higher risk of ONJ? The authors could add further information on this relationship to the discussion if available. 8 The second point for study strengths and limitations it's a conclusion. For example, the fact that in the data set are present only 5 diagnosis could be a limitation. The tobacco use is noted as risk factor for ONJ and could be also an important confounder (as noted in the last part). Maybe it's possible to identify using the ICD-9 codes disease related to tobacco use (eg COPD I found the methodology difficult to follow and lacks clarity. It may have been in an attempt to reduce the word count and unfortunately some important information was omitted. It is not in the text whether all the ONJ patients had surgical extractions. It was apparent from Figure 1 . RE: Thank you for your valuable comments. We have revised the abstract according to your suggestion. We have addressed the description of tooth extraction in the revised Methods, as well in the Limitations section. Please see the revised abstract and Method and Figure 1 . ONJ after tooth extraction (ICD-9-CM 92013C and 92014C) were then identified. Identified and excluded? RE: MRONJ is mostly due to tooth extraction. Therefore, we tried to narrow down BRONJ cases by identifying index events after tooth extraction. To avoid confusion, the section on the sampled patients has been rewritten for clarity. Please see page 8 line 9 to page 9 line 13.
VERSION 1 -AUTHOR RESPONSE
------------------------------------------------------------------------------------------- Abstract
Statistical analysis Clarify ONJ or BRONJ?
The primary endpoint of the study was to determine whether SS patients exhibit an increased risk of developing ONJ. The primary outcome of the study was to determine... or the endpoint of the study was to determine... This statement could be at the start of the methodology. RE: We have moved the description of "primary outcome" forward. In the present study, we focused on BRONJ due to the limited use of other anti-resorptive agents in Taiwan. Thank you. Please see page 8 line 10-11.
Results
At the end of the follow-up period, SS patients exhibited significantly increased incidence of ONJ compared to the controls In patients who had surgical extractions? or spontaneous development of ONJ? RE: Dentoalveolar surgery, such as tooth extraction, is one factor that is generally considered to increase the risk of BRONJ. The relative risk of BRONJ after tooth extraction in patients with cancer who are receiving BP is reportedly up to 50 times higher than that in patients receiving BP who have not undergone tooth extraction.1-4 We specifically added tooth extraction to increase the accuracy of BRONJ rather than using ICD-9CM alone. Thank you for your comments.
Discussion
We found that patients with SS were susceptible to ONJ in a population-based database.
Can it be quantified? RE: We agree with your comments. Patients with SS had a nearly 9-fold increased risk of developing BRONJ compared with patients without SS. We have added this useful information to the revised Discussion. Thank you. Please see page 13 line 2-4.
Treatment with BPs could further increase the risk of BRONJ in patients with SS compared to those without SS.
Is it for patients undergoing dental surgery? RE: We agree with your comments. Tooth extraction is a major cause of BRONJ. We have mentioned this in the relevant areas throughout the entire manuscript to avoid confusion. Please see page 8, line 15; page 11, line 9; page 13 line 3 and page 16 line 5-8.
Diabetes is associated with BRONJ following tooth extractions in rats.
Were the rats on bisphosphonates and had diabetes? Or did the rats have diabetes and developed ONJ? RE: Yes. Rats with DM that were on BPs were susceptible to BRONJ. Diabetes is associated with jaw osteonecrosis in rats undergoing alendronate therapy and subjected to tooth extractions.5 Please see page 14 line 3-4.
Whether the use of steroids increases the risk of ONJ is still controversial. The use of steroids does not increase the risk of ONJ in patients with DM ... ONJ is still controversial. However, one study found the use of steroids did not increase the risk of ONJ... RE: Changes have been made according to your suggestion. Thank you. Please see page 14 line 6-7.
-
Reviewer Name: Riham Fliefel Institution and Country: Oral and Maxillofacial Surgery Department, LMU, Munich, Germany; ExperiMed, Surrgery Department, LMU, Munich, Germany Please state any competing interests or state 'None declared': None declared.
Please leave your comments for the authors below I would like to thank the authors for their effort in the manuscript. There are few comments for the authors.
In the corresponding author: the email needs to be in the right form written. Abstract: The whole abstract needs to be re-written. RE: We have corrected the email form and revised the abstract. Thank you.
Page 5, line no. periodic dental checks: this is not a type of non-surgical treatment. Line 46: BRONJ or MRONJ. why not using the term "MRONJ" as it's the updated term. RE: We have revised the abovementioned sentence. Please see page 5 line 8-10. We agree with your comment that MRONJ is an updated term. However, there was limited use of antiresorptive medications other than BPs; therefore, we used the term BRONJ to be specific. Please see page 16, line 8-10.
Page 8, line no. 38: why did the authors started the age range from 20 years old. Why not the fourth decade (30-35). RE: Thank you for your comments. We considered enrolling adult patients only. At the end of the study, the patients were approximately 50-60 years old. We believe that changing the criteria would not cause significant alterations of the results.
Page 14, line no. 7: Steroids usage can cause osteonecrosis of the jaws. Did you exclude cases that developed osteonecrosis due to steroids usage. RE: Yes. A diagnosis of osteoporosis before the index date was an exclusion criterion in this study.
References: All the references need to be checked and please remove the description of the journal. If the date of SS diagnosis is the index date, it seems to me that it does not make sense adding that "those diagnosed with SS […] prior to the index date" were excluded" (page 8 line 46). Radiotherapy is an exclusion criterion for BRONJ, rather than a "relevant comorbidity" (page 9 line 12). Why was osteoporosis not among the conditions identified? RE: We agree with your comments that selection bias could be associated with the criterion related to tooth extraction. However, dentoalveolar surgery, such as tooth extraction, is one factor that is generally considered to increase the risk of BRONJ.1 2 The relative risk of BRONJ after tooth extraction in patients with cancer who are receiving BPs is reportedly up to 50 times higher than that in patients receiving BPs who have not undergone tooth extraction.1-4 We specifically added tooth extraction to increase the accuracy of ONJ rather than using ICD-9CM alone. We have revised this section to avoid confusion. We appreciate your comment that the case definition should include bisphosphonate use before the onset of osteonecrosis. Patients with cancer and osteoporosis prior to the index date were excluded. There was no indication of BP treatment.
We agree with your comments that osteoporosis should be evaluated. We found that osteoporosis was not a risk factor for subsequent BRONJ. Please see revised Table 3 . We also agree with your comments that radiotherapy should be an exclusion criterion. Although we did not exclude radiotherapy, radiotherapy was not an independent risk factor for BRONJ in the multivariate regression analysis. In addition, we have incorporated your comments into the revised Limitations. Data can be found in the Results section and revised Tables 1-3 .
Was it possible to distinguish between bisphosphonates with oncological indications from those prescribed for osteoporosis? RE: Thank you for your comments. We have added osteoporosis as a variable in the revised manuscript and tables. We found that osteoporosis was not an independent risk factor in the multivariate logistic regression. Please see Table 3 .
Results
According to Figure 1 the number of BISPHOSPHONATE-RELATED osteonecrosis of the jaw is 4. While it is unclear the number of BISPHOSPHONATE-RELATED cases in the group without SS. How Authors explain the high difference in the prevalence of diabetes (2 times) and malignancies (1.5 times)? Not surprisingly, the use of steroids is 75 times more common among SS patients. I wonder if this can be the only possible explanation of the difference in BRONJ incidence. Please check this hypothesis. The use of bisphosphonates as reported in the table it is not particularly useful unless it can be stratified according to the indication (metastasis vs osteoporosis). The risk is of the two types of drugs is too much different to be analysed together. RE: Propensity-matching analysis was performed in the logistic regression model. The potential confounders were age, gender and index year. The match tolerance was 0.15 with the nearest neighbour method. The study comparison cohort-matching ratio was four-fold (study: comparison=1:4). Therefore, it could cause differences in comorbidities. Please see the revised Methods on page 9, line 5; page 11, line 4. However, by using multivariate logistic regression, confounders such as osteoporosis and cancer and the use of steroids were not independent risk factors. Please see revised Methods, page 9, line 5-13 and revised Table 3 . We have revised Figure 1 1a. Please could you provide additional details on the matching process in the methods section. The methods section suggests that participants were matched on identical covariate values (age and gender). However, figure 1 contradicts this by saying propensity score matching was used. RE: We have corrected this error. Propensity-matching analysis was performed in the logistic regression model. The potential confounders were age, gender and index year. The match tolerance was 0.15 with the nearest neighbour method. The study comparison cohort-matching ratio was fourfold (study: comparison=1:4). Please see the revised Methods on page 8, line 17 to page 9, line 13.
1b. In addition, presumably the index date for the patient cohort was then assigned to the corresponding control patients, rather than this being a matching criteria since the control patients won't have a diagnosis date? RE: We appreciate your comments. Propensity-matching analysis was performed in the logistic regression model. The potential confounders were age, gender and "index year". The match tolerance was 0.15 with the nearest neighbour method. We have revised the methods to avoid confusion. Please see page 9, line 8-13.
2. The insignificant results for steroids, chemotherapy and radiotherapy could be due to the low number of events. Please mention this in the limitations and be more cautious in your conclusions regarding these results. RE: We have incorporated your comments into the revised Limitations. Please see page 15, line 16-17.
3. Please provide additional results on the interaction model. Was this adjusted for the other covariates as well as those in the interaction term? Please report the raw numbers and percentages for those in the corresponding biphosphonate x ONJ groups. RE: The interaction model was performed with Cox regression, and the covariates were adjusted as described previously in the Methods section and revised Table 3 . The raw numbers and percentages of BRONJ after tooth extraction can be found in the revised flow chart in revised Figure 1. 4. Please amend the incorrect percentage for Steroids in Table 1 (4.14.71%). RE: We have corrected the typing error. Please see revised Table 1 . Thank you.
5. This study focuses on ONJ after tooth extraction. Could it be that SS patients have higher risk of needing tooth extraction which causes higher risk of ONJ? The authors could add further information on this relationship to the discussion if available.
REVIEW RETURNED
13-Nov-2018
GENERAL COMMENTS I believe that the manuscript benefited from all the comments of the reviewers and from the changes that the authors made accordingly.
REVIEWER
Bethan Copsey
University of Oxford, United Kingdom REVIEW RETURNED 30-Oct-2018
GENERAL COMMENTS
Thank you to the authors for successfully responding to the reviewer comments.
I think the manuscript has greatly benefited from clarification of the methods and additional discussion of the limitations of this study.
I have a few minor concerns remaining.
1. Comparing Tables 1 and 2 indicates that fewer participants have osteoporosis at the end of follow-up than at baseline. Is this correct?
2. Please rename table 2 to indicate that it is the demographics at the end of the study. It includes the information from the prebaseline period so does not record incidence (i.e. new cases of hypertension, for example).
3. I think further clarification on the definition of case and control would be beneficial. The authors could spell out that BRONJ was defined as patients taking biphosponates at baseline who develop ONJ after tooth extraction.
Is it the case that the authors looked factors related to risk of ONJ and as Table 3 shows, BP use was a significant factor? If so, the authors should make this clear rather than that risk of BRONJ was a significant finding, rather than their primary hypothesis. I think the manuscript has greatly benefited from clarification of the methods and additional discussion of the limitations of this study.
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